Sirolimus-eluting iron bioresorbable scaffold versus cobalt-chromium everolimus-eluting stents in patients with coronary artery disease: Rationale and design of the IRONMAN-II trial
Study context
- Population
- Patients with CAD
- Participants
- 518 patients
- Planned comparison
- Sirolimus-eluting iron bioresorbable scaffold vs cobalt-chromium everolimus-eluting stent
- Iron bioresorbable scaffold (IBS)n = 257
- Drug-eluting stents (DES)n = 261reference
- Primary endpoint
- In-segment late lumen loss
- Follow-up
- 2 years
Methodological detailsrationale and design, noninferiority, multicentre (36 centres, China), Major secondary endpoints: 2-year quantitative flow ratio and optical coherence tomography (OCT) cross-sectional mean flow area (OCT subgroup, 25 patients per group)
- Rationale and design
- Noninferiority
- Multicentre (36 centres, China)
- Major secondary endpoints: 2-year quantitative flow ratio and OCT cross-sectional mean flow area (OCT subgroup, 25 patients per group)
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Sirolimus-eluting iron bioresorbable scaffold versus cobalt-chromium everolimus-eluting stents in patients with coronary artery disease: Rationale and design of the IRONMAN-II trial. Am Heart J. Published 4 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →